EUVIMEDEUVIMED entdecken
Crossref

Antiphospholipid antibody nephropathy in pregnancy; consequences for fetal renal development and maternal health outcomes

Maryam Kazemi, Arezoo Harsjian, Azam Moridi, Sadaf Rassouli, Zahra Hamidi Madani, Zeinab Zamanpour, Forouhar Darabi, Roya Biglarifar, Zohreh Sanjarian, Zahra Kamranirad, Sina Salem Ahim

Journal of Nephropathology · 30.04.2026 · 15 (2) · e27691

DOI: 10.34172/jnp.2026.27691 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Nephropathology, online erschienen am 10.03.2026. Verfasst von Maryam Kazemi und 10 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Antiphospholipid antibody (aPL) nephropathy in pregnancy is a critical and complex medical condition that poses significant risks to both maternal renal health and fetal development. This autoimmune disorder is characterized by the presence of aPLs, which target phospholipid-binding proteins, leading to a procoagulant state. In the context of pregnancy, this predisposition to thrombosis can manifest as thrombotic microangiopathy (TMA) within the renal vasculature, directly impacting kidney function. The resulting renal microvascular injury contributes to a decline in maternal renal health, potentially leading to proteinuria, hypertension, and even acute kidney injury, exacerbating the already delicate physiological changes of pregnancy. The intricate interplay between autoimmune-mediated thrombosis and placental dysfunction is central to the high-risk nature of this condition. aPLs can cause thrombosis in the placental vasculature, leading to placental insufficiency, intrauterine growth restriction, preeclampsia, and recurrent pregnancy loss. This compromise in placental blood flow not only jeopardizes fetal development but also indirectly strains maternal renal function. The systemic inflammation and endothelial dysfunction associated with aPLs further complicate the clinical picture, making accurate diagnosis and timely intervention paramount for managing these multifaceted challenges. Effective management of aPL nephropathy in pregnancy necessitates a highly individualized and multidisciplinary approach, focusing on meticulous monitoring of both maternal and fetal well-being. This includes close surveillance of renal function, blood pressure, and proteinuria, alongside regular assessments of fetal growth and placental health. Therapeutic strategies often involve anticoagulation with heparin, sometimes combined with low-dose aspirin, to mitigate the thrombotic risk. Such precise monitoring and tailored interventions are crucial for optimizing outcomes, aiming to preserve maternal renal health while supporting successful fetal development in this challenging clinical scenario.

Zitieren

APA

Kazemi, M., Harsjian, A., Moridi, A., Rassouli, S., Madani, Z. H., Zamanpour, Z., Darabi, F., Biglarifar, R., Sanjarian, Z., Kamranirad, Z., & Ahim, S. S. (2026). Antiphospholipid antibody nephropathy in pregnancy; consequences for fetal renal development and maternal health outcomes. Journal of Nephropathology, 15(2), e27691. https://doi.org/10.34172/jnp.2026.27691

Vancouver

Kazemi M, Harsjian A, Moridi A, Rassouli S, Madani ZH, Zamanpour Z, et al. Antiphospholipid antibody nephropathy in pregnancy; consequences for fetal renal development and maternal health outcomes. Journal of Nephropathology. 2026;15(2):e27691. doi:10.34172/jnp.2026.27691

BibTeX
@article{Kazemi2026,
  author = {Kazemi, Maryam and Harsjian, Arezoo and Moridi, Azam and Rassouli, Sadaf and Madani, Zahra Hamidi and Zamanpour, Zeinab and Darabi, Forouhar and Biglarifar, Roya and Sanjarian, Zohreh and Kamranirad, Zahra and Ahim, Sina Salem},
  title = {Antiphospholipid antibody nephropathy in pregnancy; consequences for fetal renal development and maternal health outcomes},
  journal = {Journal of Nephropathology},
  year = {2026},
  volume = {15},
  number = {2},
  pages = {e27691},
  doi = {10.34172/jnp.2026.27691}
}
Kostenlos starten →